Close Menu

Lung Cancer

News and reporting on lung cancer.

Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.

The initiative's four research projects will use use genetic and other technologies to detect and treat cancer at its earliest stages.

The test measures levels of seven autoantibodies in patient blood to aid in the early detection of lung cancer.

The NGS-based test, which was approved by the FDA in June, will be now available to the insurers' members, who have non-small cell lung cancer, in four states.

The developers hope that the NSCLC detection system they are developing could eventually be expanded to include biomarkers for other cancer types and diseases.

The firm plans to launch its first test from the lab, a mRNA-based noninvasive confirmatory lung diagnostic, by the end of this year.

The agreement is to support the company’s analytical and preanalytical research and assist in its trials aimed at a number of cancers.  

Recent work by researchers from Harvard and Moffitt Cancer Center demonstrated the potential usefulness of radiomics in combination with gene expression data.

The firm is approaching launch of its lung cancer test with new sales hires planned, but saw its Q2 net loss miss the consensus Wall Street estimate.